Nirma closes in on Glenmark's API arm, emerges sole contender as bid deadline ends

Nirma Group is likely to acquire an 82.84% stake in Glenmark Life Sciences in a deal worth INR 6,664 to INR 7,000 crore. The company has emerged as the sole bidder following the deadline last week, with the acquisition likely to be facilitated by healthcare subsidiary Aculife Healthcare.

Related Keywords

India ,Bengaluru ,Karnataka ,Samara ,Samarskaya Oblast ,Russia ,Ahmedabad ,Gujarat ,Hindustan ,India General ,China ,Mumbai ,Maharashtra ,Chinese ,Kotak Mahindra ,Karsanbhai Patel ,Glenn Saldanha ,Lafarge Holcim ,Nirma Aculife ,Sekhmet Pharmaventures ,Stericon Pharma ,Hindustan Lever Ltd ,Axis Bank ,Hindustan Unilever Ltd ,Glenmark Life Sciences ,Nirma Group ,Glenmark Pharmaceuticals ,Standard Chartered Bank ,Aculife Healthcare ,Core Parenterals ,Samara Capital ,Chartered Bank ,Emami Cement ,Nirma ,Parenteral ,Api Platform ,Semami ,